Transplantation. T-cell depletion--balancing acute rejection and cancer risk.
The authors of a new study suggest that the proinflammatory state of acute rejection combined with the use of T-cell-depleting antibody therapy might explain the increased risk of cancer after kidney transplantation. However, their findings do not fully support this conclusion; use of T-cell-depleting antibodies alone is likely to increase cancer risk.
Division of Nephrology, David Geffen School of Medicine at UCLA, 7-155 Factor Building, 10833 Le Conte Boulevard, Los Angeles, CA 90095-1689, USA.
Uttam G
UG
Reddy
Division of Nephrology, David Geffen School of Medicine at UCLA, 7-155 Factor Building, 10833 Le Conte Boulevard, Los Angeles, CA 90095-1689, USA.
Gabriel M
GM
Danovitch
D001323:Autoantibodies / Q000009:adverse effects*; D005260:Female; D006084:Graft Rejection / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D013601:T-Lymphocytes / Q000276:immunology*; D014565:Urogenital Neoplasms / Q000276:immunology*
D001323:Autoantibodies; D007166:Immunosuppressive Agents